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the CSF and the adjacent brain tissue. Long-term neu-
rological sequelae and death are caused jointly by the
following factors: (1) The systemic inﬂammatory response
of the host leads to leukocyte extravasation into the sub-
arachnoid space, an increased CSF outﬂow resistance, and
brain edema. The resulting elevated intracranial pressure
is an important cause of death in the acute phase and
of long-term sequelae. Systemic inﬂammation can also
cause vasculitis, cerebral venous thrombosis and secondary
ischemia. (2) Immune cells within the brain parenchyma,
in particular microglia, can be stimulated by proinﬂam-
matory bacterial compounds, which can directly lead to
neuronal injury. (3) Some bacterial compounds, e.g., pneu-
molysin, possess direct toxicity on neurons. Neuronal injury
is mediated by the release of reactive oxygen intermedi-
ates, proteases, cytokines and excitatory amino acids, the
activation of transcription factors, caspases, matrix metal-
loproteases and other proteases.
Rapid initiation of effective antibiotic therapy sterilizes
the CSF and reduces mortality of bacterial meningitis. In
industrialized countries, dexamethasone as an adjunctive
therapy to antibiotic treatment, improves outcome of bac-
terial meningitis, particularly of Streptococcus pneumoniae
meningitis. In experimental meningitis, dexamethasone as
an adjunct to antibiotic treatment causes an increase of
neuronal injury in the dentate gyrus of the hippocampal
formation, suggesting that corticosteroids might not be the
ideal adjunctive therapy. Several approaches that inter-
fere selectively with the mechanisms of neuronal injury,
including the use of non-bacteriolytic bactericidal protein
synthesis-inhibiting antibiotics, antioxidants and inhibitors
of transcription factors, matrix metalloproteinases, and cas-
pases, are effective in animal models. However, adequate
clinical studies are lacking. A recent randomized clinical
study points to a beneﬁcial effect of adjunctive oral glyc-
erol.
doi:10.1016/j.ijid.2010.02.2228
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Vaccination Against Bacterial Meningitis
H. Peltola
Helsinki, Finland
Thanks to conjugate vaccines specially against
Haemophilus inﬂuenzae (Hib) and Streptococcus pneu-
moniae (Pnc), bacterial meningitis has become disease
whose global importance is no more realized in the afﬂuent
countries. However, more than 1 MI individuals a year,
proportionally more often children than adults, fall down;
one-third succumb, and one-third of survivors are left
with moderate-to-severe sequelae. In the world where the
meningitis problem is greatest, only a fraction of people
are vaccinated. The main (though not only) reason is the
too high cost of conjugates for those populations.
Years ago, inexpensive polysaccharide vaccines were
developed against Hib, Pnc, and Neisseria meningitidis
(Mnc). The Hib, polysaccharide is rightly gone, but all poten-
tial of polysaccharides against Pnc and Mnc has not been
used. The reasoning is that polysaccharides are not suf-
ﬁciently immunogenic in small children (in greatest risk).
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owever, convincing clinical efﬁcacy data are lacking to
rove this statement. It is unlikely that those data will ever
e produced, because people are too convinced of the supe-
iority of conjugates to support any major ﬁeld trial with a
nc or Mnc polysaccharide.
At present, variable conjugate vaccines are available
gainst Hib, 7-13 serotypes of Pnc, and up to 4 serogroups of
nc. Hib vaccination is indicated in all countries. So is also
nc conjugate, albeit its effect speciﬁcally against meningi-
is depends on local epidemiology (serotype distribution).
n case of Mnc meningitis, the main problem is the lack
f sufﬁciently good vaccine against serogroup B, the most
ommon group in many countries. Fortunately, encouraging
esults have been obtained recently regarding a new-type
f vaccine.
Group A Mnc is a special problem of Africa. Monovalent
onjugate has been used there, and luckily, its price is tol-
rable because of its manufacturing outside Big Farma. This
pproach would be welcome to cover other causative agents
f meningits as well.
oi:10.1016/j.ijid.2010.02.2229
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ffective Adjuvant Therapies for Meningitis
. Singhi
Post-graduate Institute of Medical Education and Research,
handigarh, India
Objective: To review advances in adjuvant therapy of
acterial meningitis.
Data Sources: Work published within past 5 years
etrieved from personal knowledge and the U.S. National
ibrary of Medicine for terms: central nervous system infec-
ions, meningitisbacterial; therapy; corticosteroids; ﬂuids;
nti-inﬂammatory; glycerol, and pediatrics.
Study Selection, Data Extraction and Synthesis: Promis-
ng articles were reviewed and data used based on clinical
elevance and signiﬁcance.
Results: Corticosteroid therapy: Results from clinical
rials of adjuvant steroid therapy are conﬂicting. What
merges from meta-analysis is that in high-income countries
teroids reduce the risk of hearing loss in immunocompetent
atients with H. inﬂuenzae-b or pneumococcal meningitis;
here is no survival beneﬁt. In low-income countries utility
f corticosteroids is unclear.
Fluids: Evidence supports normal maintenance intra-
enous ﬂuids rather than restricted ﬂuids in the ﬁrst 48 hours
n settings; it reduces risk of spasticity and severe neurologic
equelae.
Oral glycerol therapy during ﬁrst 48 hours of treatment
an prevent severe neurologic sequelae. Within 6 hours of
dministration oral glycerol increased plasma osmolality by
%, which is known to reduce secretion of CSF and enhance
ovement of water back to plasma, and thus improve cere-
ral blood ﬂow.
Management of raised ICP is not easy because a variety
f mechanisms. Neuroimaging may be helpful in selection
f appropriate treatment. Cerebral perfusion pressure tar-
eted therapy to maintain CPP >50mmHg is likely to improve
he outcome.
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safe in the treatment of uncomplicated malaria in children
aged 4 months to 16 years. Arco is a suitable ACT in the332 14
New Adjunct Therapies: Endogenous inﬂammatory medi-
tors, chemokines and chemo attractant cytokines are
elieved to contribute to neurologic injury. Agents aimed
t blocking these mediators offer future therapeutic hopes:
hese have been shown to reduce brain edema, postmenin-
itic hearing loss and cochlear and brain cell injury in
xperimental meningitis. and Conclusions: In acute bac-
erial meningitis use of glycerol and maintenance instead
f restricted ﬂuids improve the outcomes; however, role
f dexamethasone in prevention of hearing loss needs re-
valuation.
oi:10.1016/j.ijid.2010.02.2230
arasitology (Oral Presentation)
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ne year impact of a single dose of Praziquantel in ﬁve
chistosomiasis endemic districts in Rwanda
. Denise1,∗, R. Eugene1, S. Jackson2, K. Blaise3, M.
dette2, K. Michee3, K. Michael2, R. Josh4
Access Project, KIGALI, Rwanda
Ministry of Health, Kigali, Rwanda
Access Project, Kigali, Rwanda
Earth Institute, Columbia University, New York, NY, USA
Background: Schistosomiasis is one of the most prevalent
arasitic diseases in developing countries and has a negative
mpact on the health of the population and consequently
he economics of those countries. In Rwanda, the mapping
urvey of schistosomiasis (and soiltransmitted helminths)
onducted in 2007 by the Neglected Tropical Disease (NTD)
ontrol program have shown that only S. mansoni was preva-
ent at 2.7% in the whole country with a variation per district
rom 0 to 69.5%. The disease was more localized near lakes
urera, Ruhondo, Muhazi and Kivu. In total, height endemic
istricts were identiﬁed and a mass drug administration with
raziquantel and albendazole was implemented.
Methods: The impact of the treatment programme was
onitored through a cohort of 2,166 school children aged 7-
6 years in ﬁve most infected districts. Their infection status
ith S. mansoni was determined by clinical and parasitologi-
al examination at baseline and at year one after treatment.
he prevalence and intensity of S. mansoni before and after
he treatment were analyzed.
Results: After one round of treatment, the prevalence of
. mansoni infection have been reduced signiﬁcantly in all 5
istricts from 11.2% [95% CI 9.8%-12.5%] at baseline to 2.0%
95% CI 1.4%-2.6%] at year one follow up. On the intensity,
he median number of eggs in the 5 districts decreased by
wo from 72 eggs per gram (epg) of stool to 36 epg. The
roportion of children with heavy S. mansoni infection was
igniﬁcantly reduced as well. Signs of early clinical morbidity
f S. mansoni infection like bloody diarrhea, abdominal pain
ecreased signiﬁcantly.The rate of hepatomegaly, which is a
ate clinical sign for S.mansoni was very low in that cohort.
t
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Conclusion: One single dose of praziquantel in school age
hildren in schistosomiasis endemic districts can decrease
igniﬁcantly the prevalence and intensity of the infection
nd can contribute to the reduction of the morbidity due to
. mansoni in Rwanda.
oi:10.1016/j.ijid.2010.02.2231
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comparative study of Arco and Coartem in the treatment
f uncomplicated malaria in patients aged 4 months to 16
ears attending Mulago hospital, Kampala, Uganda
. Rujumba1, E.A. Mworozi 1,∗, A.K. Maganda2, R. Kiguba1,
. Rwakimali 3, S. Nsobya4
Makerere University College of Health Sciences, Kampala,
ganda
Mulago National Referral Hospital, kampala, Uganda
Ministry of Health, Kampala, Uganda
Mulago Hospital, kampala, Uganda
Background: Malaria is a major cause of child morbidity
ndmortality in Uganda. It accounts for 24-45% of outpatient
isits in Uganda. The situation is worsened by the devel-
pment of drug resistance and lengthy anti-malaria drug
reatment which pose problems of compliance to medica-
ion. Both Arco and Coartem are Artemisinin Combination
herapies (ACTs). We conducted a study to compare the efﬁ-
acy and safety of Arco a single dose drug and Coartem in
he treatment of uncomplicated malaria in children aged
months — 16 years attending Mulago Hospital, Kampala
ganda.
Methods: A phase II single blinded randomized clinical
rial was carried out between November 2007 and June 2008.
e screened 3344 patients with fever for malaria of whom
53 had positive blood smear, 225 fulﬁlled the inclusion cri-
eria and were randomized into the two study arms i.e. Arco
nd Coartem arms. The study patients were followed up for
2 days.
Results: There was 100% parasite clearance by day 2 in
oth the ARCO and Coartem arms of the study. The overall
ure rate on day 42 of follow up was 98% for both Arco and
oartem. Recrudescence occurred in 2 patients in the Arco
rm of the study by day 42 and in 2 patients on Coartem
y day 21 of follow up. No statistically signiﬁcant differ-
nce in resolution of fever, vomiting, dizziness and back
ain was observed throughout the follow up period of the
tudy. No difference was observed in the clinical presenta-
ion between the two treatment arms. No serious adverse
vents were reported/observed in either of the study arms.
Conclusion: Arco and Coartem are equally effective andreatment of uncomplicated malaria in children.
oi:10.1016/j.ijid.2010.02.2232
